it is recommended that women stop taking Rybelsus for up to two months before they become pregnant
The legal issue at hand is whether Novo Nordisk, the manufacturer of Ozempic, Wegovy, and Rybelsus, knew of the risks of these gastrointestinal complications based on the results of their clinical trials but failed to adequately warn doctors and users of these risks
In trials of the branded molecules, tirzepatide produced larger average weight loss (~2022% vs ~15%)
Wegovy, Ozempic, and Rybelsus vary in purpose and outcomes, with Wegovy leading in average weight loss and Ozempic in blood sugar reduction
Previously, Wegovy was approved for people who met specific body mass index (BMI) criteria for having obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater)